FDA Announces New Sentinel System Newsletter - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. FDA Announces New Sentinel System Newsletter Today, the Food and Drug Administration's (FDA) Sentinel System released the inaugural issue of the Sentinel Newsletter. Sentinel aims to improve how FDA monitors medical product safety issues. The quarterly Sentinel Newsletter highlights upcoming Sentinel events, recently published Sentinel reports, and promotes opportunities to get involved with Sentinel public events. The newsletter is intended for those interested in staying up-to-date on Sentinel – including epidemiologists, patient advocates, informaticists, and others from government and industry. The first issue of the Sentinel Newsletter is published on the Sentinel Website. The newsletter will be delivered by subscription each quarter, please subscribe here. Authorized in 2007 by the Food and Drug Administration Amendments Act (FDAAA), the Sentinel System is a core feature of the FDA's postmarket safety system that can rapidly evaluate potential safety risks related to the use of medical products. Sentinel enhances the FDA's ability to proactively monitor the safety of prescription drugs and other regulated products after they have reached the market. This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA